ScreenerHero

PYXS Pyxis Oncology, Inc.

NAS · US · Healthcare · Biotechnology · pyxisoncology.com
1.920USD-4.48%Mkt Cap: 240.11M $P/E: —

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consist…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap240.11M USD
Enterprise Value153.32M USD
Revenue (TTM)11.04M USD
Gross Profit11.47M USD
Net Income (TTM)-79.62M USD
Revenue/Share0.17 USD
Last Price1.920 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees56
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.79
PEG—
EV/EBITDA-1.79
EV/Revenue13.89
P/S21.86
P/B11.22
EPS (TTM)-1.26
EPS (Forward)-1.13
52W Range
1.03020% of range5.550
52W High5.550 USD
52W Low1.030 USD
Profitability
Gross Margin82.77%
Oper. Margin-812.74%
EBITDA Margin0.00%
Profit Margin-574.55%
ROE-149.08%
ROA-87.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-63.50M USD
CapEx (TTM)9.00K USD
FCF Margin-210.06%
FCF Yield-9.66%
Net Debt-15.16M USD
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity0.35
Current Ratio1.34
Quick Ratio1.20
Book Value/Sh0.18 USD
Cash/Share0.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.667 USD
Upside (mean)+351.4%
Target Range6.000 USD – 19.00 USD
6.000+351.4% to mean19.00
# Analysts9
Ownership
Shares Out.119.46M
Float59.21M
Insiders9.47%
Institutions34.12%
Short Interest
Short Ratio5.0d
Short % Float7.00%
Short % Out.5.61%
Shares Short4.68M
Short (prev mo.)4.43M
Technical
SMA 503.143 (-38.9%)
SMA 2002.124 (-9.6%)
Beta1.38
S&P 52W Chg16.45%
Avg Vol (30d)1.26M
Avg Vol (10d)1.74M
Technical Indicators
RSI (14)30.7
MACD-0.2956
MACD Signal-0.1603
MACD Hist.-0.1354
BB Upper4.134 USD
BB Middle2.941 USD
BB Lower1.748 USD
BB Width81.14%
ATR (14)0.2839 USD
Vol Ratio (20d)0.62x